Please login to the form below

Not currently logged in
Email:
Password:

Truxima

This page shows the latest Truxima news and features for those working in and with pharma, biotech and healthcare.

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

Daily Brief: Theresa May and the diabetes sensor, Biosimilars hit Roche in Europe, Gilead CEO to step down

period. A number of biosimilar versions of the drug hit European markets last year, including Celltrion's Truxima, (pictured), marketed by Mundipharma and other firms across the region, and this year

Latest news

  • Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

    This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera. ... With Remsima, we achieved market

  • Roche faces biosimilar blitz in 2018 Roche faces biosimilar blitz in 2018

    Novartis’ unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab).

  • Roche faces prospect of second Rituxan biosimilar in US Roche faces prospect of second Rituxan biosimilar in US

    It was the second biosimilar of Roche's drug to be approved in Europe after Celltrion/Mundipharma's Truxima, which also pipped Sandoz to the filing post in the US after

  • Standing out in a crowd Standing out in a crowd

    It followed that this year by gaining approval from the European Commission for the world’s first monoclonal antibody biosimilar of MabTera (rituximab), marketed as Truxima.

  • Sandoz joins Europe's MabThera biosimilar push Sandoz joins Europe's MabThera biosimilar push

    The approval - which comes four months after Celltrion/Mundipharma's Truxima biosimilar was cleared for marketing by the EMA - is for the entire range of indications awarded to MabThera, including ... Truxima claimed the distinction of being the first

More from news
Approximately 1 fully matching, plus 7 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
W2O Group

W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics